Medical Disclaimer
  • Educational Only: Not for clinical decision-making.
  • Verify Information: Always consult protocols and authoritative sources.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.
Bedside Snapshot
  • Core dose: Hyperkalemia with ECG changes: 1 g (10 mL of 10%) IV over 2–5 min, may repeat; CCB toxicity: 1 g over 5–10 min, repeat every 10–20 min to effect (often 2–4 g total)
  • Onset/duration: Onset within minutes for membrane stabilization; duration 30–60 min (hyperkalemia); does not lower K⁺—only stabilizes membrane
  • Key danger: Severe tissue necrosis with extravasation (potent vesicant)—prefer central line; bradycardia/arrhythmia if given too rapidly; precipitates with bicarbonate (flush line between)
  • Special: 10% solution provides ~27 mg/mL elemental Ca²⁺ (~1.36 mEq/mL); membrane stabilizer in hyperkalemia; antidote for CCB toxicity and hypermagnesemia; contains 3× more elemental calcium than calcium gluconate
Brand & Generic Names
  • Generic Name: calcium chloride (10% solution for injection)
  • Brand Names: CaCl₂ 10% injection (various manufacturers; no single proprietary IV brand is dominant)
Medication Class

Electrolyte; membrane stabilizer; antidote (hyperkalemia, hypermagnesemia, calcium channel blocker toxicity)

Pharmacology

Mechanism of Action:

  • Supplies ionized calcium to restore transmembrane gradients and stabilize cardiac myocyte membranes
  • Antagonizes the membrane effects of hyperkalemia and hypermagnesemia (does not lower K⁺ or Mg²⁺ concentrations)
  • In calcium channel blocker toxicity, increases extracellular Ca²⁺ to overcome competitive blockade at L-type channels and improve contractility/AV conduction

Key Pharmacokinetics / Product Facts:

  • Concentration: 10% calcium chloride contains about 27 mg/mL elemental calcium (~1.36 mEq/mL). A 10 mL dose ≈ 272 mg elemental Ca²⁺ (≈13.6 mEq)
  • Onset IV: minutes for ECG/membrane stabilization
  • Duration: Clinical effect in hyperkalemia typically lasts 30–60 minutes
  • Distribution: Primarily in the extracellular fluid; not dialyzable as an antidote effect
  • Vesicant: Significant risk of tissue necrosis with extravasation—prefer central line when feasible
Indications
  • Membrane stabilization in life-threatening hyperkalemia with ECG changes (peaked T waves, widened QRS, sine-wave)
  • Hypermagnesemia with hypotension, heart block, or respiratory depression
  • Calcium channel blocker (CCB) overdose (e.g., verapamil/diltiazem/amlodipine) as part of multimodal therapy
  • Symptomatic hypocalcemia (e.g., post-massive transfusion citrate toxicity, acute hypocalcemia with tetany/seizures)
  • Hydrofluoric acid exposure (systemic toxicity) as adjunct when severe—local therapy typically uses calcium gluconate
  • Note: Not recommended for routine cardiac arrest use; reserve for the above specific indications
Conditions Treated
  • Life-threatening hyperkalemia with ECG changes
  • Hypermagnesemia (symptomatic)
  • Calcium channel blocker overdose/toxicity
  • Symptomatic hypocalcemia
  • Massive transfusion citrate toxicity
  • Hydrofluoric acid systemic toxicity
Dosing & Administration

Available Forms:

  • 10% solution (100 mg/mL calcium chloride ≈ 27 mg/mL elemental Ca²⁺; ~1.36 mEq/mL)

Adult Dosing:

Indication Dose Notes
Hyperkalemia with ECG changes 1 g (10 mL of 10%) IV over 2–5 min Reassess ECG after 5–10 min; may repeat if changes persist. Duration ~30–60 min
Hypermagnesemia (symptomatic) 1 g IV over 5–10 min Repeat as needed to reverse cardiorespiratory effects
CCB toxicity 1 g IV over 5–10 min; repeat every 10–20 min to effect Often 2–4 g total. Consider continuous infusion (0.2–0.5 mL/kg/h of 10%) with ionized calcium monitoring
Symptomatic hypocalcemia 500 mg–1 g IV over 5–10 min May follow with infusion titrated to ionized calcium

Pediatric Dosing:

  • 20 mg/kg of 10% calcium chloride (0.2 mL/kg; max 1 g) slow IV/IO for hypocalcemia or membrane stabilization
  • For hyperkalemia with ECG changes, similar dosing may be used with close monitoring

Administration:

  • Give via central line when possible
  • If peripheral, ensure large-bore, well-running IV and slow rate with frequent site checks
  • Use separate line from bicarbonate/phosphate to prevent precipitation
Contraindications

Contraindications:

  • Hypercalcemia
  • Relative: Digoxin (digitalis) toxicity—IV calcium can precipitate dysrhythmias; avoid unless life-threatening hyperkalemia with ECG instability, and if used, give cautiously with expert input

Precautions:

  • Avoid mixing or co-infusing with sodium bicarbonate or phosphate solutions—precipitation risk (line incompatibility). Flush lines well between drugs
  • Extravasation risk: tissue necrosis and calcinosis cutis—monitor site closely; stop infusion immediately if pain/swelling/whitening occurs
  • Neonates: avoid concomitant ceftriaxone with IV calcium due to risk of precipitation; follow age-specific guidance
Extravasation Risk: Significant risk of tissue necrosis with extravasation. Prefer central line when feasible.
Adverse Effects

Cardiovascular:

  • Bradycardia
  • Hypotension (especially with rapid bolus)
  • Arrhythmias
  • Syncope

Local Reactions:

  • Burning
  • Pain
  • Phlebitis
  • Severe tissue injury with extravasation

Other:

  • Nausea, vomiting
  • Metallic or chalky taste
  • Flushing
  • Peripheral vasodilation
  • Hypercalcemia with excessive or repeated dosing—monitor ionized calcium
Clinical Pearls
CaCl₂ vs Gluconate: Calcium chloride provides about 3 times more elemental calcium per mL than calcium gluconate and has more predictable IV bioavailability; choose CaCl₂ when rapid effect is critical and central access is available.
Peripheral Access: If only peripheral access is available, calcium gluconate is generally preferred due to lower extravasation risk; if CaCl₂ must be used peripherally, run slowly and monitor the site continuously.
Hyperkalemia Endpoint: ECG is the endpoint in hyperkalemia—not the serum potassium. Repeat bolus if QRS remains wide or T waves remain markedly peaked.
CCB Overdose Management: In CCB overdose, combine with high-dose insulin euglycemia therapy, vasopressors (e.g., norepinephrine), and consider lipid emulsion for select lipophilic agents; calcium alone is often insufficient.
Post-Massive Transfusion: Anticipate citrate-induced hypocalcemia; target ionized calcium in the normal range (e.g., ≥1.0–1.2 mmol/L) while avoiding overshoot.
Compatibility: Do not co-administer with bicarbonate or phosphate; separate lines or flush thoroughly. Avoid Y-site with ceftriaxone in neonates.
Extravasation Management: Stop infusion, leave catheter, aspirate any residual drug, elevate limb; consider hyaluronidase per institutional protocol and apply cold or warm compress per extravasation policy.
References
  • 1. Papadopoulos, J. (2008). Pocket guide to critical care pharmacotherapy. Humana Press.
  • 2. Medscape. (n.d.). Calcium chloride (intravenous) – drug monograph & dosing. Retrieved 2025-11-12, from https://reference.medscape.com
  • 3. Medscape. (n.d.). Hyperkalemia: Treatment & management. Retrieved 2025-11-12, from https://emedicine.medscape.com/article/240903-treatment
  • 4. Medscape. (n.d.). Calcium channel blocker toxicity: Treatment. Retrieved 2025-11-12, from https://emedicine.medscape.com/article/2184611-treatment
  • 5. DrugBank Online. (n.d.). Calcium chloride. Retrieved 2025-11-12, from https://go.drugbank.com
Back to Medication Index